TR200002206A2 - 6-hidroksi--3-(4-[2-(piperidin-1-İL)Etoksi]Fenoksi)-2-(4- Metoksifenil) Benzo[b]Tiyofen hidroklorür' ün yeni kristal formu. - Google Patents

6-hidroksi--3-(4-[2-(piperidin-1-İL)Etoksi]Fenoksi)-2-(4- Metoksifenil) Benzo[b]Tiyofen hidroklorür' ün yeni kristal formu.

Info

Publication number
TR200002206A2
TR200002206A2 TR2000/02206A TR200002206A TR200002206A2 TR 200002206 A2 TR200002206 A2 TR 200002206A2 TR 2000/02206 A TR2000/02206 A TR 2000/02206A TR 200002206 A TR200002206 A TR 200002206A TR 200002206 A2 TR200002206 A2 TR 200002206A2
Authority
TR
Turkey
Prior art keywords
piperidin
benzo
methoxyphenyl
phenoxy
ethoxy
Prior art date
Application number
TR2000/02206A
Other languages
English (en)
Turkish (tr)
Inventor
Kay Bush Julie
Charles Conrad Preston
Gerard Flom Merlyn
Douglas Luke Wayne
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR200002206A2 publication Critical patent/TR200002206A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR2000/02206A 1999-07-29 2000-07-27 6-hidroksi--3-(4-[2-(piperidin-1-İL)Etoksi]Fenoksi)-2-(4- Metoksifenil) Benzo[b]Tiyofen hidroklorür' ün yeni kristal formu. TR200002206A2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14628699P 1999-07-29 1999-07-29
US14757099P 1999-08-06 1999-08-06
US14977399P 1999-08-19 1999-08-19

Publications (1)

Publication Number Publication Date
TR200002206A2 true TR200002206A2 (tr) 2001-03-21

Family

ID=27386379

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02206A TR200002206A2 (tr) 1999-07-29 2000-07-27 6-hidroksi--3-(4-[2-(piperidin-1-İL)Etoksi]Fenoksi)-2-(4- Metoksifenil) Benzo[b]Tiyofen hidroklorür' ün yeni kristal formu.

Country Status (44)

Country Link
EP (1) EP1204656A2 (fr)
JP (1) JP2001064277A (fr)
KR (1) KR100697177B1 (fr)
CN (1) CN1138770C (fr)
AR (1) AR031073A1 (fr)
AT (1) AT502318A1 (fr)
AU (1) AU6335600A (fr)
BE (1) BE1013411A3 (fr)
BR (1) BR0003209A (fr)
CA (1) CA2314682A1 (fr)
CO (1) CO5180570A1 (fr)
CZ (1) CZ299311B6 (fr)
DE (1) DE10036854A1 (fr)
DK (1) DK200001151A (fr)
DZ (1) DZ3060A1 (fr)
FI (1) FI20001722L (fr)
FR (1) FR2796944B1 (fr)
GB (1) GB2352717A (fr)
GR (1) GR1004084B (fr)
HR (1) HRP20000503B1 (fr)
HU (1) HUP0003001A2 (fr)
ID (1) ID27078A (fr)
IL (1) IL137553A (fr)
IT (1) IT1318660B1 (fr)
LT (1) LT4790B (fr)
LU (1) LU90617B1 (fr)
LV (1) LV12623B (fr)
MD (1) MD2336G2 (fr)
MX (1) MXPA00007461A (fr)
MY (1) MY128764A (fr)
NL (1) NL1015821C2 (fr)
NO (1) NO20003879L (fr)
PE (1) PE20010385A1 (fr)
PL (1) PL341749A1 (fr)
PT (1) PT102502A (fr)
RO (1) RO121851B1 (fr)
SE (1) SE0002792L (fr)
SG (1) SG91296A1 (fr)
SI (1) SI20426A (fr)
SV (1) SV2002000132A (fr)
TR (1) TR200002206A2 (fr)
TW (1) TWI276437B (fr)
UA (1) UA72885C2 (fr)
WO (1) WO2001009116A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208384T3 (es) * 1999-07-29 2004-06-16 Eli Lilly And Company Forma cristalina de clorhidrato de 6 hidroxi-3-(4-(2-(piperidin-1-il)-etoxi)-fenoxi)2--(4-metoxifenil)-benzo(b)tiofeno.
CA2691739A1 (fr) * 2000-05-08 2001-11-15 Eli Lilly And Company Formulations stabilisees de 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene et sels de ces composes
US7122203B2 (en) 2000-05-08 2006-10-17 Eli Lilly And Company Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
EP1757291A3 (fr) * 2000-05-08 2009-07-15 Eli Lilly & Company Formulations stabilisées de 6-hydroxy-3-(4- 2-(pipéridin-1-yl)éthoxyphénoxy)-2-(4-methoxyphényl) benzo(b)thiophène et sels de ces composés
EP1157996A1 (fr) * 2000-05-23 2001-11-28 JENAPHARM GmbH Nouveaux formes solides du mesoprogestin 11beta-(4E-(hxdroxyiminomethyl)-phenyl)-17alpha-methoxymethyl-17beta-methoxy-estra-4,9-dien-3-on
CZ20031098A3 (cs) * 2000-10-20 2003-08-13 Eli Lilly And Company Nová krystalická forma 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]fenoxy)-2-(4-methoxyfenyl)benzo[b]thiofen hydrochloridu
AU2002230409A1 (en) 2000-11-27 2002-06-03 Eli Lilly And Company Process for preparing 3-aryl-benzo(b)thiophenes
CA2393720C (fr) * 2002-07-12 2010-09-14 Eli Lilly And Company Monochlorhydrate de 3-(1-methyl-1h-indol-3-yl)-4-[[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole-2,5-dione cristallin
PL1773811T3 (pl) * 2004-07-22 2011-02-28 Lilly Co Eli Krystaliczny zmienny hydrat soli hemibursztynianowej (s)-6-(4-(2-((3(9h-karbazol-4-iloksy)-2-hydroksypropylo)amino)-2-metylopropylo)fenoksy)-3-pirydynokarboksy amidu

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
JP3989569B2 (ja) * 1995-02-28 2007-10-10 イーライ リリー アンド カンパニー ベンゾチオフェン化合物、中間体、組成物および方法
ZA9710262B (en) * 1996-11-19 1999-05-13 Lilly Co Eli Process for the synthesis of benzothiophenes
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.

Also Published As

Publication number Publication date
WO2001009116A2 (fr) 2001-02-08
KR20010049916A (ko) 2001-06-15
DK200001151A (da) 2001-01-30
DZ3060A1 (fr) 2004-05-22
SV2002000132A (es) 2002-06-07
CN1288007A (zh) 2001-03-21
RO121851B1 (ro) 2008-06-30
NL1015821A1 (nl) 2001-01-30
PE20010385A1 (es) 2001-04-06
AT502318A1 (de) 2007-02-15
NO20003879L (no) 2001-01-30
FI20001722A7 (fi) 2001-01-30
BE1013411A3 (fr) 2001-12-04
FI20001722L (fi) 2001-01-30
FI20001722A0 (fi) 2000-07-28
GR20000100265A (el) 2001-03-30
LV12623A (en) 2001-03-20
UA72885C2 (uk) 2005-05-16
MD2336G2 (ro) 2004-06-30
HUP0003001A2 (hu) 2002-04-29
CA2314682A1 (fr) 2001-01-29
EP1204656A2 (fr) 2002-05-15
KR100697177B1 (ko) 2007-03-21
IL137553A (en) 2005-09-25
LV12623B (en) 2001-07-20
SE0002792D0 (sv) 2000-07-28
HRP20000503A2 (en) 2001-06-30
NO20003879D0 (no) 2000-07-28
JP2001064277A (ja) 2001-03-13
PT102502A (pt) 2001-01-31
SG91296A1 (en) 2002-09-17
NL1015821C2 (nl) 2002-01-03
MD2336F2 (en) 2003-12-31
GB0018641D0 (en) 2000-09-13
LT2000076A (lt) 2001-02-26
AU6335600A (en) 2001-02-19
GR1004084B (el) 2002-12-11
MXPA00007461A (es) 2004-07-16
PL341749A1 (en) 2001-02-12
CZ299311B6 (cs) 2008-06-18
LT4790B (lt) 2001-05-25
ITMI20001759A0 (it) 2000-07-28
HRP20000503B1 (en) 2008-04-30
GB2352717A (en) 2001-02-07
FR2796944A1 (fr) 2001-02-02
BR0003209A (pt) 2001-03-20
CO5180570A1 (es) 2002-07-30
CZ20002716A3 (en) 2001-05-16
WO2001009116A3 (fr) 2001-05-17
SI20426A (sl) 2001-06-30
IE20000605A1 (en) 2001-04-04
MD20000162A (en) 2001-04-30
TWI276437B (en) 2007-03-21
MY128764A (en) 2007-02-28
ID27078A (id) 2001-02-22
IL137553A0 (en) 2001-07-24
LU90617B1 (fr) 2001-06-15
SE0002792L (sv) 2001-01-30
CN1138770C (zh) 2004-02-18
AR031073A1 (es) 2003-09-10
DE10036854A1 (de) 2001-03-01
FR2796944B1 (fr) 2003-01-31
HU0003001D0 (en) 2000-10-28
ITMI20001759A1 (it) 2002-01-28
HK1035370A1 (en) 2001-11-23
IT1318660B1 (it) 2003-08-27

Similar Documents

Publication Publication Date Title
TR200002205A2 (tr) 6-hidroksi--3-(4-[2-(Piperidin-1-İL)Etoksi] Fenoksi)-2-(4-Metoksifenil) Benzo [b] Tiyofen hidroklorür'ün yeni kristal formu
US7399867B2 (en) Selective estrogen receptor modulators containing a phenylsulfonyl group
EP0976398A3 (fr) Utilisation de dérivés diphényl-3,4 chromane dans la fabrication d'un médicament pour diminuer le taux de cholestérol et inhiber la prolifération de cellules de muscles lisses, l'endométriose et la maladie utérine fibreuse
JP2003520817A5 (fr)
ATE272629T1 (de) Benzothiophene
SE0002792D0 (sv) Ny kristallin form av 6-hydroxi-3-(4-§2-(piperidin-1-yl)-etoxi¤fenoxi)-2-(4-metoxifenyl)benso§b¤tiofen-hydroklorid
KR910011817A (ko) 중추 신경계 약제로서 유용한 치환 시클로헥센
ECSP034560A (es) UNA NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6-HIDROXI-3-(4-(2-(PIPERIDIN-1-IL)ETOXI)FENOXI)-2-(4-METOXIFENIL) BENZO (b) TIOFENO
JPH10130260A5 (fr)
DE69916672D1 (de) Androsteron-Derivate, deren Verwendung zur Unterdrückung der Bindung des Aktivatorproteins AP-1 an die DNA wie der Vermehrung der glatten Muskelzellen der Atemwege
ATE348605T1 (de) Stabilisierte formulierungen von 6-hydroxy-3-(4- (2-(piperidin-1-yl)ethoxy)phenoxy)-2-(4- methoxyphenyl)benzo(b)thiophen und deren salze
FI120345B (fi) Bentsotiofeeniyhdisteet, välituotteet, koostumukset ja menetelmät
ATE263164T1 (de) Bentzothiophene
WO2004014360A3 (fr) Compositions pharmaceutiques destinees au traitement de l'incontinence urinaire
ZA200003838B (en) A novel chrystalline form of 6-hydroxy-3-(4-[2-)piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride.
ES1044138U (es) Anillo para relacion sexual.
HUP9902404A3 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-choloro-1,3-dihydro-2(2h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist
RU97112206A (ru) Применение соединения с прогестеронантагонистическим и эстрогенантагонистическим действием для получения лекарственных средств для женской контрацепции
KR20050019912A (ko) 페닐술포닐기를 함유하는 선택적 에스트로겐 수용체 조절제